Utilisation of primary and secondary G-CSF prophylaxis enables maintenance of optimal dose delivery of standard adjuvant chemotherapy for early breast cancer: An analysis of 1655 patients

被引：9

作者：

Chan, Arlene ^{[1
,2
]}

McGregor, Scott ^{[2
]}

Liang, Wenbin ^{[3
]}

机构：

[1] Curtin Univ, Perth, WA 6000, Australia

[2] Breast Canc Res Ctr WA, Perth, WA 6000, Australia

[3] Curtin Univ, Hlth Sci, Natl Drug Res Inst, Perth, WA 6000, Australia

来源：

BREAST | 2014年 / 23卷 / 05期

关键词：

Relative dose intensity; G-CSF use; First cycle nadir; Breast cancer; RANDOMIZED-TRIAL; CYCLOPHOSPHAMIDE; NEUTROPENIA; DOCETAXEL; 5-FLUOROURACIL; METHOTREXATE; DOXORUBICIN; EPIRUBICIN; PREDICTORS; INTENSITY;

D O I：

10.1016/j.breast.2014.07.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Optimal outcome for early breast cancer patients receiving adjuvant chemotherapy requires adequate dose delivery, commonly defined as >85% of planned dose of chemotherapy agents. Outside the clinical trial setting, reports from community oncology centres have demonstrated that a significant proportion of patients fail to receive this dose intensity, with neutropenia being the most commonly cited reason for sub-optimal treatment. Data collected prospectively on 1655 patient treated in a single breast cancer centre demonstrates that patients at risk of sub-optimal dose delivery can be identified by routine assessment of neutropenic events during the first cycle. The uniform administration of secondary G-CSF for all subsequent cycles enables dose delivery >= 85%, which was shown to lead to improved survival outcomes when compared with those patients who received <85%. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：676 / 682

页数：7

共 45 条

[31] Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022 [J].

Keita Uchino ;

Shingo Tamura ;

Shoji Kimura ;

Keisuke Shigeta ;

Takahiro Kimura ;

Yukinori Ozaki ;

Hiroshi Nishio ;

Kenji Tsuchihashi ;

Eiki Ichihara ;

Makoto Endo ;

Shingo Yano ;

Dai Maruyama ;

Tetsuhiro Yoshinami ;

Nobuyuki Susumu ;

Munetaka Takekuma ;

Takashi Motohashi ;

Mamoru Ito ;

Eishi Baba ;

Nobuaki Ochi ;

Toshio Kubo ;

Yutaro Kamiyama ;

Shinji Nakao ;

Shinobu Tamura ;

Hitomi Nishimoto ;

Yasuhisa Kato ;

Atsushi Sato ;

Toshimi Takano ;

Yuji Miura .

International Journal of Clinical Oncology, 2024, 29 :545-550

[32] Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens [J].

D Genre ;

P Viens ;

F Bertucci ;

C Chabannon ;

G Gravis ;

A-C Braud ;

J Camerlo ;

G Houvenaeghel ;

V Moutardier ;

A Goncalvez ;

C Protière ;

V-J Bardou ;

D Maraninchi .

Bone Marrow Transplantation, 2002, 29 :881-886

[33] Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer:: comparative evaluation of completion and safety of three intensive regimens [J].

Genre, D ;

Viens, P ;

Bertucci, F ;

Chabannon, C ;

Gravis, G ;

Braud, AC ;

Camerlo, J ;

Houvenaeghel, G ;

Moutardier, V ;

Goncalvez, A ;

Protière, C ;

Bardou, VJ ;

Maraninchi, D .

BONE MARROW TRANSPLANTATION, 2002, 29 (11) :881-886

[34] Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial [J].

Bekes, Inga ;

Eichler, Martin ;

Singer, Susanne ;

Friedl, Thomas W. P. ;

Harbeck, Nadia ;

Rack, Brigitte ;

Forstbauer, Helmut ;

Dannecker, Christian ;

Huober, Jens ;

Kiechle, Marion ;

Lato, Krisztian ;

Janni, Wolfgang ;

Fink, Visnja .

CLINICAL BREAST CANCER, 2020, 20 (06) :439-447

[35] Effects of primary granulocyte-colony stimulating factor prophylaxis on neutropenic toxicity and chemotherapy dose delivery in Chinese patients with breast cancer who received adjuvant docetaxel plus cyclophosphamide chemotherapy: a retrospective cohort study [J].

Kwok, Carol C. H. ;

Wong, W. H. ;

Chan, Landon L. ;

Wong, Sabrina P. Y. ;

Wang, F. ;

Wong, Martin C. S. ;

Tse, Shelly L. A. .

HONG KONG MEDICAL JOURNAL, 2022, 28 (06) :438-446

[36] Adjuvant Docetaxel and Cyclophosphamide (DC) with Prophylactic Granulocyte Colony-Stimulating Factor (G-CSF) on Days 8 & 12 in Breast Cancer Patients: A Retrospective Analysis [J].

Yerushalmi, Rinat ;

Goldvaser, Hadar ;

Sulkes, Aaron ;

Ben-Aharon, Irit ;

Hendler, Daniel ;

Neiman, Victoria ;

Ciuraru, Noa Beatrice ;

Bonilla, Luisa ;

Amit, Limor ;

Zer, Alona ;

Granot, Tal ;

Rizel, Shulamith ;

Stemmer, Salomon M. .

PLOS ONE, 2014, 9 (10)

[37] Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC) [J].

Mark Clemons ;

Sasha Mazzarello ;

John Hilton ;

Anil Joy ;

Julie Price-Hiller ;

Xiaofu Zhu ;

Shailendra Verma ;

Anne Kehoe ;

Mohammed FK Ibrahim ;

Marta Sienkiewicz ;

Carol Stober ;

Lisa Vandermeer ;

Brian Hutton ;

Ranjeeta Mallick ;

Dean Fergusson .

Supportive Care in Cancer, 2019, 27 :1345-1354

[38] Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapy [J].

Reinisch, Mattea ;

Bruzas, Simona ;

Gluz, Oleg ;

Ataseven, Beyhan ;

Schmid, Peter ;

Cortes, Javier ;

Blohmer, Jens-Uwe ;

Shenoy, Satyendra ;

Dyson, Mark H. ;

Dittmer-Grabowski, Christine ;

Chiari, Ouafaa ;

Harrach, Hakima ;

Gebauer, Daniel ;

Traut, Alexander ;

Kuemmel, Sherko .

MOLECULAR ONCOLOGY, 2023, 17 (06) :1060-1075

[39] High-dose chemotherapy with autologous bone marrow support as consolidation after standard-dose adjuvant therapy in primary breast cancer patients with seven or more involved axillary lymph nodes [J].

RI Lalisang ;

PSGJ Hupperets ;

MA ten Haaft ;

RLH Jansen ;

HC Schouten .

Bone Marrow Transplantation, 1998, 21 :243-247

[40] High-dose chemotherapy with autologous bone marrow support as consolidation after standard-dose adjuvant therapy in primary breast cancer patients with seven or more involved axillary lymph nodes [J].

Lalisang, RI ;

Hupperets, PSGJ ;

ten Haaft, MA ;

Jansen, RLH ;

Schouten, HC .

BONE MARROW TRANSPLANTATION, 1998, 21 (03) :243-247

← 1 2 3 4 5 →